Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Incyte (INCY) Sell-Off on Opzelura Miss an 'Overreaction' - Truist
August 2, 2022 12:45 PM EDTTruist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $95.00 price target on Incyte (NASDAQ: INCY), saying the stock pullback from the Opzelura miss is an overreaction.
The analyst commented, "While JAKAFI beat cons ($598M vs. $587M), stock weak on... More
Incyte (INCY) Tops Q2 EPS by 45c
August 2, 2022 7:08 AM EDTIncyte (NASDAQ: INCY) reported Q2 EPS of $1.01, $0.45 better than the analyst estimate of $0.56. Revenue for the quarter came in at $911 million versus the consensus estimate of $814.9 million.
For earnings history and earnings-related data on Incyte (INCY) click here.
... More